PL2854858T3 - Formulacja rysperydonu w postaci implantu - Google Patents

Formulacja rysperydonu w postaci implantu

Info

Publication number
PL2854858T3
PL2854858T3 PL13726003.0T PL13726003T PL2854858T3 PL 2854858 T3 PL2854858 T3 PL 2854858T3 PL 13726003 T PL13726003 T PL 13726003T PL 2854858 T3 PL2854858 T3 PL 2854858T3
Authority
PL
Poland
Prior art keywords
risperdal
implant formulation
implant
formulation
risperdal implant
Prior art date
Application number
PL13726003.0T
Other languages
English (en)
Inventor
Ibon Gutierro Aduriz
Guillermo Franco Rodríguez
Original Assignee
Laboratorios Farmacéuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2854858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmacéuticos Rovi, S.A. filed Critical Laboratorios Farmacéuticos Rovi, S.A.
Publication of PL2854858T3 publication Critical patent/PL2854858T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13726003.0T 2012-05-31 2013-05-31 Formulacja rysperydonu w postaci implantu PL2854858T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170362.3A EP2529756B1 (en) 2011-05-31 2012-05-31 Risperidone and/or Paliperidone implant formulation
PCT/EP2013/061320 WO2013178812A1 (en) 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation

Publications (1)

Publication Number Publication Date
PL2854858T3 true PL2854858T3 (pl) 2026-04-20

Family

ID=46147376

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12170362T PL2529756T3 (pl) 2011-05-31 2012-05-31 Formulacja implantu zawierającego rysperydon i/lub paliperydon
PL13726003.0T PL2854858T3 (pl) 2012-05-31 2013-05-31 Formulacja rysperydonu w postaci implantu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12170362T PL2529756T3 (pl) 2011-05-31 2012-05-31 Formulacja implantu zawierającego rysperydon i/lub paliperydon

Country Status (32)

Country Link
EP (2) EP2529756B1 (pl)
JP (1) JP6367795B2 (pl)
KR (1) KR101880716B1 (pl)
CN (1) CN104363923A (pl)
AU (1) AU2013269547B2 (pl)
BR (1) BR112014029209A2 (pl)
CA (1) CA2874765C (pl)
CL (1) CL2014003216A1 (pl)
CO (1) CO7160108A2 (pl)
CY (1) CY1124369T1 (pl)
DK (2) DK2529756T3 (pl)
EA (1) EA031819B1 (pl)
ES (2) ES2878112T3 (pl)
FI (1) FI2854858T3 (pl)
HR (2) HRP20260301T1 (pl)
IL (1) IL235849B (pl)
IN (1) IN2014DN10672A (pl)
LT (2) LT2529756T (pl)
MA (1) MA37664B1 (pl)
MX (1) MX374955B (pl)
MY (1) MY174999A (pl)
NZ (1) NZ703321A (pl)
PH (1) PH12014502667B1 (pl)
PL (2) PL2529756T3 (pl)
PT (2) PT2529756T (pl)
RS (1) RS62059B1 (pl)
SG (1) SG11201407961WA (pl)
SI (2) SI2529756T1 (pl)
SM (1) SMT202100448T1 (pl)
UA (1) UA119430C2 (pl)
WO (1) WO2013178812A1 (pl)
ZA (1) ZA201409299B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
EP2529756B1 (en) * 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or Paliperidone implant formulation
EP2394664B1 (en) 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (es) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
JP2008509144A (ja) 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
US8314110B2 (en) 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
CN101677952B (zh) * 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (en) * 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2009015828A1 (en) 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
EP2394664B1 (en) * 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
EP2529756B1 (en) * 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or Paliperidone implant formulation
SI2394663T1 (sl) * 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata

Also Published As

Publication number Publication date
CY1124369T1 (el) 2022-07-22
LT2529756T (lt) 2021-07-26
SI2854858T1 (sl) 2026-04-30
EP2529756A2 (en) 2012-12-05
CN104363923A (zh) 2015-02-18
EP2529756A3 (en) 2013-08-07
ZA201409299B (en) 2015-12-23
ES3064200T3 (en) 2026-04-23
FI2854858T3 (fi) 2026-03-03
CA2874765C (en) 2020-06-02
IN2014DN10672A (pl) 2015-08-28
CO7160108A2 (es) 2015-01-15
PL2529756T3 (pl) 2021-11-15
SG11201407961WA (en) 2014-12-30
JP6367795B2 (ja) 2018-08-01
MX374955B (es) 2025-03-06
JP2015518036A (ja) 2015-06-25
UA119430C2 (uk) 2019-06-25
KR101880716B1 (ko) 2018-08-17
HRP20211057T1 (hr) 2021-10-01
PT2529756T (pt) 2021-07-28
EA031819B1 (ru) 2019-02-28
WO2013178812A1 (en) 2013-12-05
RS62059B1 (sr) 2021-07-30
SI2529756T1 (sl) 2021-09-30
CL2014003216A1 (es) 2015-07-10
CA2874765A1 (en) 2013-12-05
ES2878112T3 (es) 2021-11-18
AU2013269547B2 (en) 2018-03-15
KR20150016964A (ko) 2015-02-13
MA37664B1 (fr) 2016-11-30
SMT202100448T1 (it) 2021-09-14
EA201401346A1 (ru) 2015-04-30
EP2854858B1 (en) 2025-12-10
DK2529756T3 (da) 2021-08-02
NZ703321A (en) 2017-01-27
EP2854858A1 (en) 2015-04-08
PH12014502667A1 (en) 2015-02-02
MX2014014483A (es) 2015-02-24
AU2013269547A1 (en) 2015-01-22
PH12014502667B1 (en) 2020-01-22
EP2529756B1 (en) 2021-05-19
IL235849A0 (en) 2015-01-29
MY174999A (en) 2020-06-01
LT2854858T (lt) 2026-03-10
MA37664A1 (fr) 2016-03-31
IL235849B (en) 2019-03-31
HRP20260301T1 (hr) 2026-04-10
BR112014029209A2 (pt) 2017-06-27
DK2854858T3 (da) 2026-03-09
PT2854858T (pt) 2026-03-06

Similar Documents

Publication Publication Date Title
DK2854858T3 (da) Risperidon implantatformulering
EP3818947C0 (en) Fenestrated implant
HRP20211423T4 (hr) Formulacije enzalutamida
IL236916B (en) Implant encapsulation
IL224867A0 (en) Dexmedetomidine premix formulation
BR112015006198A2 (pt) conjunto de cadeira
HRP20161771T1 (hr) Formulacije bendamustina
DK2668967T3 (da) Implantat
EP2846781A4 (en) PROLIPOSOMAL TESTOSTERONE FORMULATIONS
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
EP2814487A4 (en) FORMULAS FROM BENDAMUSTIN
EP2827862A4 (en) FORMULAS FROM BENDAMUSTIN
BR112014000015A2 (pt) formulação
ZA201306000B (en) Stable formulation
DK2729012T3 (da) Mælkebaseret formulering
SG11201405958RA (en) Nicotine formulation
DK2877155T3 (da) Opioidformuleringer
DK4082524T3 (da) Triazinformuleringer
HUE045947T2 (hu) Formuláció IBS kezelésére
FR2998474B1 (fr) Implant intraoculaire trans-irien
FR2995524B1 (fr) Prothese endo-urinaire
EP2770828A4 (en) FORMULATION
PT2908835T (pt) Formulações estáveis
EP2773204A4 (en) Pazopanib FORMULATION